Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending

被引：0
|
作者：
Michaeli, D. T. [1 ]
Michaeli, C. T. [2 ]
机构：
[1] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[2] UMM Univ Klinikum Mannheim, Abteilung Personalisierte Onkol Schwerpunkt Lung, Mannheim, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2650
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1696MO
引用
收藏
页码：S927 / S927
页数：1
相关论文
共 50 条
  • [31] Study Characteristics and Risk of Bias of Clinical Trials Supporting FDA Approval of Cardiovascular Drugs, 2006–2020
    Meijun Shu
    Siliang Chen
    Jiarui Li
    Journal of General Internal Medicine, 2022, 37 : 2888 - 2893
  • [32] Many FDA-approved cancer drugs might lack clinical benefit
    Das, Manjulika
    LANCET ONCOLOGY, 2018, 19 (02): : E82 - E82
  • [33] Racial and ethnic enrollment disparities in clinical trials leading to FDA approval of gynecologic cancer treatment
    Scalia, Peter
    Gilbert, Lucy
    Bernard, Laurence
    Zeng, Xing
    Franco, Luis Pareja
    Levin, Gabriel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A83 - A83
  • [34] Study Characteristics and Risk of Bias of Clinical Trials Supporting FDA Approval of Cardiovascular Drugs, 2006-2020
    Shu, Meijun
    Chen, Siliang
    Li, Jiarui
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (11) : 2888 - 2893
  • [35] Tumor response rate for hematologic and solid cancer drugs with FDA approval supported by single-arm trials
    Michaeli, D. T.
    Michaeli, J. C.
    Mossialos, E.
    Albers, S.
    Michaeli, C. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S508 - S508
  • [36] Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020
    Jenei, Kristina
    Meyers, Daniel
    Gyawali, Bishal
    JAMA NETWORK OPEN, 2023, 6 (01) : e2253438
  • [37] Clinical evidence and benefit of special FDA designations in anti-cancer drugs.
    Michaeli, Daniel Tobias
    Michaeli, Julia Caroline
    Albers, Sebastian
    Boch, Tobias
    Winterhoff, Boris
    Michaeli, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
    Bloem, Lourens T.
    Bot, Rosa E.
    Mantel-Teeuwisse, Aukje K.
    van der Elst, Menno E.
    Sonke, Gabe S.
    Klungel, Olaf H.
    Leufkens, Hubert G. M.
    Hoekman, Jarno
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (05) : 2169 - 2179
  • [39] Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)
    Molto Valiente, C.
    Borrell, M.
    Ocana Fernandez, A.
    Templeton, A. J.
    del Carpio, L. P.
    Del Paggio, J.
    Barnadas, A.
    Booth, C. M.
    Tibau, A.
    Amir, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 564 - 564
  • [40] Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period
    Bujosa, Aida
    Molto, Consolacion
    Hwang, Thomas J.
    Carlos Tapia, Jose
    Vokinger, Kerstin N.
    Templeton, Arnoud J.
    Gich, Ignasi
    Barnadas, Agusti
    Amir, Eitan
    Tibau, Ariadna
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (13): : 117 - 125
12345